From penetrating solid tumors to new success rates for de novo design, the next wave of antibody therapies aims to transform the clinic.

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...

Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...

The emergence of antibody-drug conjugates (ADCs) has seen them become a promising class of anticancer therapeutics, exhibiting better precision and reduced off-target toxicity in targeting cancer ...

What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...

A new HIC–MS method using ammonium tartrate improves ADC characterization, enabling efficient drug-to-antibody ratio analysis without complex workflows. A proteomics workflow combining laser ablation ...